Rocky Mountain Chocolate Factory reported a net loss of $1.3 million for fiscal Q2 2027, with revenue stable at $6.7 million compared to the previous year. The company improved gross margin to 8.0% due to pricing and production efficiencies but faced higher costs from expanded store operations. They completed a $6.6 million sale-leaseback of their Durango facility to repay debt and secured a $2 million loan for working capital. The board is exploring strategic alternatives including potential sale or merger to enhance long-term shareholder value.
Rocky Mountain Chocolate Factory's fiscal Q2 2027 results provide context for market watchers. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 134 priced US stocks, 53 rose and 80 fell. Notable movers include Abercrombie & Fitch Co. (ANF) at USD 161.94 with a 1-day change of +5.66%, Best Buy Co Inc (BBY) at USD 93.99 up 5.49%, and Sea Limited (SE) at USD 88.68 down 5.43%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
